Quotient Clinical Rebrands as Quotient Sciences

Nov 14, 2017

Quotient Clinical, the drug development services organization, announces its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma and SeaView Research. This new identity signifies a global footprint and an extended range of services, and symbolizes the commitment to ensuring a consistent and high-quality experience for customers.

With 700 employees and five operating sites across the United States and the United Kingdom, Quotient is focused on delivering a portfolio of innovative services encompassing formulation development, clinical trial and commercial manufacturing, and clinical pharmacology.

Quotient’s Translational Pharmaceutics platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research, transforming the traditional industry approach of outsourcing to independent contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs). Translational Pharmaceutics is proven to accelerate development timelines and reduce overall costs.

“We are excited about the future of Quotient Sciences,” said Mark Egerton, CEO, Quotient Sciences. “By integrating services typically found in disparate CDMOs and CROs, we break down barriers and support our customers to improve R&D productivity and accelerate the delivery of new medicines to patients around the world. We have a 30-year track record of service to a global customer base, including large multinational pharmaceutical companies to smaller virtual biotech organizations.”

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments